Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects
NCT ID: NCT06671821
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
81 participants
INTERVENTIONAL
2024-11-20
2025-09-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Safety and Tolerability of Multiple Doses of HRS-7535 in Obese Subjects
NCT06621316
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
NCT06904105
Efficacy and Safety of HRS-7535 Tablets in Obese Subjects .
NCT06250946
Efficacy and Safety of HRS9531 Tablet in Obese Subjects
NCT06841445
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
NCT07150962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
HRS-7535
HRS-7535
Group B
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
HRS-7535
HRS-7535
Group C
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
HRS-7535
HRS-7535
Group D
Subjects will receive escalated dose of HRS-7535 or maximum tolerated dose orally
HRS-7535
HRS-7535
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HRS-7535
HRS-7535
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects who have completed the entire 36-week treatment course of the HRS-7535-202 trial.
3. Subjects who have a full understanding of the trial content, processes, and possible adverse reactions, and are capable and willing to comply with the protocol requirements to complete this study.
Exclusion Criteria
2. Pregnant, lactating, planning to conceive during the trial period, or fertile subjects unwilling to take effective contraceptive measures during the trial period.
3. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong Suncadia Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HRS-7535-202-Extension
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.